– USA, CA – RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Dr. Mary Tagliaferri (M.D.) to its board of directors effective September 29, 2021.
“I am pleased to welcome Mary as a valuable addition to our board of directors. Her direct leadership in pioneering novel cancer therapeutics lends her to be a great thought partner as we advance our portfolio to become the leader in targeted radiopharmaceuticals,” said CEO, Dr. Ken Song.
About Dr. Mary Tagliaferri
Dr. Mary Tagliaferri has a highly accomplished biotechnology career and is currently Executive Clinical Fellow and SVP of Nektar Therapeutics, where she also previously served as CMO. She has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and was also instrumental in establishing key strategic partnerships. She also serves on the board of Enzo Biochem.
“Targeted radiopharmaceuticals offer an exciting new platform for the development of potential breakthrough therapies for cancer,” commented Dr. Mary Tagliaferri. “I am highly impressed with RayzeBio’s leadership in this exciting field and their efficient creation of a scientifically rigorous discovery and development engine, which has led to proprietary insights on how to advance this emerging therapeutic modality.”
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020.
For more information: https://rayzebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
